With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...
Eli Lilly announces $15 billion share buyback plan and 15% dividend boost amidst mixed technical signals. Investors are ...
Eli Lilly and Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 ...
Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head ...
The sales surge signals the chip maker’s continued momentum amid the artificial-intelligence boom, though investors weren't ...
The Series A round was led by Ego Death Capital, with participation from Plan B Bitcoin Fund, Timechain, and Solit Group.
U.S. stock futures were mostly higher early Tuesday as investors anticipated the final inflation reading of the year. Futures on the S&P 500 were 0.1% higher ahead of the open, Nasdaq 100 futures were ...
Stocks, bonds and the dollar saw small moves, with traders unwilling to make any significant bets as they await key inflation data for clues on whether the Federal Reserve will cut or hold rates next ...
A blood test being developed by Roche and Eli Lilly that could help diagnose patients with Alzheimer’s disease more quickly has been awarded breakthrough status by the FDA, which could help it ...